Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of inebilizumab in adults with generalized myasthenia gravis
CTR20210474Phase 3Active
- Sponsor
- Viela Bio
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inebilizumab in myasthenia gravis (MG), sponsored by Viela Bio. Started Sep 2021; status: active.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20210474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210474.